By If you or someone you love has taken Ozempic and later developed severe stomach problems or sudden vision loss, you have probably heard the term “Ozempic lawsuit” being mentioned in the news or by an attorney.
In short, the Ozempic lawsuit refers to a growing wave of legal claims filed against Novo Nordisk, the manufacturer of Ozempic, by patients who say the popular diabetes and weight loss drug caused them serious, sometimes permanent, injuries that the company failed to properly warn them about. These cases are not isolated incidents. As of August 2026, thousands of people across the United States have joined this litigation, and the numbers keep climbing every month.
This article breaks down exactly what the Ozempic lawsuit is about, who qualifies to file an Ozempic lawsuit, what injuries are at the center of the litigation, how the Ozempic lawsuit legal process works, and what you can realistically expect if you decide to pursue a claim. Whether you are a patient trying to understand your options or simply someone following the headlines, this guide will walk you through the full picture in plain language.
Table of Contents
What Is the Ozempic Lawsuit About?
At its core, the Ozempic lawsuit is a product liability case. Plaintiffs allege that Novo Nordisk knew, or reasonably should have known, that Ozempic and other GLP-1 receptor agonist drugs could cause severe gastrointestinal injuries and vision problems, yet the company did not adequately warn doctors or patients about these risks on the drug’s label. Because Ozempic was marketed so aggressively for both diabetes management and weight loss, millions of people started taking it without ever being told they could face life altering side effects.
The Ozempic lawsuit is not a single case sitting in one courtroom. Instead, an Ozempic lawsuit is really a collection of individual lawsuits that have been consolidated for efficiency. The litigation involving GLP-1 medications, primarily Ozempic and Wegovy, is advancing on multiple fronts, with federal lawsuits alleging gastroparesis and other severe gastrointestinal injuries consolidated in a multidistrict litigation known as MDL 3094 in the Eastern District of Pennsylvania, along with a separate, newer MDL addressing claims of sudden vision loss. This structure allows courts to handle shared questions of fact and evidence together, while each plaintiff’s individual damages are still evaluated on their own merits.
The Two Main Injury Categories Driving the Ozempic Lawsuit
Almost every Ozempic lawsuit filed today falls into one of two broad injury categories, and understanding them is the first step to knowing whether an Ozempic lawsuit applies to your situation.
Gastrointestinal injuries: The majority of claims involve gastroparesis, a condition in which the stomach muscles stop functioning normally and food cannot move through the digestive system the way it should. This leads to chronic nausea, vomiting, bloating, and in severe cases, hospitalization or surgery. Related claims also cover ileus and intestinal obstruction. Roughly seventy five percent of complaints in the MDL allege gastroparesis or stomach paralysis, about eighteen percent involve ileus, and around eight percent involve gallbladder injuries.
Vision loss: A newer but rapidly growing category of the Ozempic lawsuit centers on NAION, or non-arteritic anterior ischemic optic neuropathy, a form of sudden and often permanent vision loss that typically affects one eye. In December 2025, a federal panel combined Ozempic and related GLP-1 vision loss lawsuits into a separate multidistrict litigation in the Eastern District of Pennsylvania.
Why People Are Filing an Ozempic Lawsuit
Understanding why so many people are turning to legal action helps explain the scale of the Ozempic lawsuit litigation. Ozempic, along with sister drugs like Wegovy, Rybelsus, and Mounjaro, belongs to a class of medications called GLP-1 receptor agonists. These drugs slow down digestion, which is part of why they help control blood sugar and reduce appetite. But that same mechanism appears to be linked to serious digestive complications in a subset of users.
Plaintiffs in the Ozempic lawsuit generally argue one or more of the following legal theories.
- Failure to warn, meaning the manufacturer did not disclose known or foreseeable risks on the label
- Design defect, meaning the drug itself carries an unreasonable risk of harm
- Negligence, meaning the company did not act with reasonable care in researching, testing, or marketing the drug
- Breach of warranty, meaning the drug did not perform as safely as represented
Every Ozempic lawsuit filed so far shares a common thread. Patients say they trusted their doctors and the drug’s label, took the medication as prescribed, and then suffered an injury they were never warned could happen.
How the Ozempic Lawsuit Litigation Is Structured
Because so many individuals were filing similar claims in different federal courts, a panel stepped in to centralize the Ozempic lawsuit cases. This is a common process in mass tort litigation, and it is exactly what happened with the Ozempic lawsuit.
MDL 3094: The Gastrointestinal Injury Docket
As of August 2026, there are nearly four thousand personal injury lawsuits for gastroparesis, ileus, and intestinal obstruction pending in MDL 3094 in the Eastern District of Pennsylvania, with federal judge Karen S. Marston presiding over the litigation. This docket has grown steadily since it was first formed, and new cases continue to be filed on a near daily basis as more patients connect their injuries to the medication.
MDL 3163: The Vision Loss Docket
Separate from the gastrointestinal claims, a second multidistrict litigation was created specifically to handle NAION and vision loss claims. The U.S. Judicial Panel on Multidistrict Litigation created this separate MDL for cases alleging that GLP-1 drugs including Ozempic, Wegovy, Mounjaro, and Trulicity cause permanent vision loss. This case count is smaller than the gastrointestinal docket but is expanding quickly as awareness of the NAION connection spreads.
State Court Cases
Not every Ozempic lawsuit is filed in federal court, and state level Ozempic lawsuit cases are playing an important role in the overall litigation. A New Jersey Multicounty Litigation is also handling claims related to sudden vision loss and gastrointestinal injuries, since Novo Nordisk’s United States headquarters is based in New Jersey. State court consolidation works similarly to an MDL, allowing courts to manage overlapping cases more efficiently while preserving each plaintiff’s individual claim.
Where the Ozempic Lawsuit Stands Right Now
An Ozempic lawsuit of this size does not move quickly, and it is important to set realistic expectations. The litigation is still in its early stages, and there have not been any trials or settlements finalized yet.No global settlements had been announced as of August 2026.
That said, the case is progressing through important pretrial milestones. A Rule 702 expert hearing is scheduled for September 2026 to address warnings, preemption, and general causation, which will determine whether the plaintiffs’ expert causation testimony is admissible at trial. Bellwether trial selection is still expected around mid-2026, with the first trials possible in late 2026, while any broader mass settlement is considered unlikely before late 2027.
Bellwether trials are a standard part of mass tort litigation. A small number of representative cases go to trial first, and the outcomes help both sides understand how juries are likely to respond to the evidence. These early results often shape how future settlement negotiations unfold, which is why so many people watch bellwether trial dates closely when following an Ozempic lawsuit update, and why every Ozempic lawsuit filed today is being tracked as part of this larger process.
A Real Look at How These Claims Play Out
Consider a fairly typical scenario that mirrors what many plaintiffs describe in their filings. A patient in her late forties was prescribed Ozempic to manage type 2 diabetes. Within several months, she began experiencing persistent vomiting, severe abdominal pain, and an inability to keep food down. After multiple emergency room visits, she was diagnosed with gastroparesis and eventually required a feeding tube. Her medical records documented the timeline clearly: prescription, escalating symptoms, formal diagnosis, and ongoing treatment. This is precisely the kind of documented injury pattern that forms the backbone of a successful Ozempic lawsuit, and it illustrates why medical documentation matters so much when preparing an Ozempic lawsuit claim.
Who Qualifies to File an Ozempic Lawsuit
Not everyone who took Ozempic and later felt sick qualifies for an Ozempic lawsuit. Courts require a clear, documented connection between the drug and the injury. Generally speaking, a person may have grounds to pursue an Ozempic lawsuit if they can show the following.
- They were prescribed and took Ozempic, Wegovy, Rybelsus, or a comparable GLP-1 drug
- They were later diagnosed with gastroparesis, ileus, bowel obstruction, gallbladder disease, or NAION
- The diagnosis is supported by objective medical evidence, not just a doctor’s clinical impression
- The injury required hospitalization, surgery, emergency treatment, or ongoing medical care
- They did not have a pre-existing condition that would independently explain the injury
That third point matters more than many people realize. The court has ruled that any plaintiff claiming to suffer from gastroparesis must have a diagnosis confirmed by objective medical evidence, meaning a doctor’s clinical impression alone is not enough. This is one of the biggest hurdles claimants face, which is why gathering thorough medical records early is so important.
Families of patients who died after developing severe complications may also be able to bring a wrongful death Ozempic lawsuit as part of the broader litigation.
What Damages Can Be Recovered
If an Ozempic lawsuit claim is successful, either through a settlement or a jury verdict, plaintiffs in an Ozempic lawsuit may be entitled to compensation for several categories of harm.
- Past and future medical expenses, including hospitalization, surgery, and long-term care
- Lost wages and diminished earning capacity if the injury affected the ability to work
- Pain and suffering associated with the physical and emotional toll of the injury
- Loss of enjoyment of life, particularly in vision loss cases where daily activities are permanently affected
- Punitive damages in situations where evidence shows the manufacturer knew of the risks and failed to act
On the topic of punitive damages, attorneys handling the Ozempic lawsuit argue that these may be appropriate here. Punitive damages may be awarded in cases where it can be shown that the manufacturer knew the risk of harm associated with using the drug and failed to warn consumers, putting profits over patients. Whether that argument succeeds will likely become clearer once the first bellwether trials conclude.
Be cautious about predicted settlement values circulating online. Because no bellwether trial has concluded and no global Ozempic lawsuit settlement framework exists yet, any number quoted for a potential payout is, at best, an early estimate rather than a guarantee.
The Regulatory Backdrop
Understanding the regulatory history helps explain why the Ozempic lawsuit litigation gained so much traction. Ozempic has always carried a boxed warning related to thyroid C-cell tumors based on rodent studies, and it is contraindicated for patients with a personal or family history of certain thyroid cancers. However, gastroparesis and NAION were not clearly reflected on the original label. In January 2025, the FDA added ileus warnings to Ozempic’s label. Plaintiffs argue this update came far too late for patients who were already injured, and that earlier, clearer warnings could have changed how doctors prescribed the drug and how patients monitored their symptoms.
Independent research has also fueled the litigation. A study published in JAMA in 2023 reported that GLP-1 users had a substantially higher risk of bowel obstruction compared with users of another weight loss drug, alongside elevated risk of gastroparesis and pancreatitis. Findings like this are cited in court filings as evidence the risks were knowable before the label was updated.
How the Legal Process Typically Unfolds
If you are considering whether to file an Ozempic lawsuit, it helps to understand the general path an Ozempic lawsuit claim follows, even though every case has its own timeline.
Step One: Case Evaluation
An attorney reviews your medical history, prescription records, and diagnosis to determine whether your Ozempic lawsuit meets the threshold for filing. This step usually happens at no upfront cost, since most firms work on a contingency basis.
Step Two: Filing and Consolidation
Once an Ozempic lawsuit is filed, it is typically transferred into the appropriate MDL, either MDL 3094 for gastrointestinal injuries or the newer NAION docket, depending on the nature of the injury.
Step Three: Discovery and Expert Review
Both sides exchange evidence and bring in medical experts to testify about causation. This is the phase the Ozempic lawsuit is currently working through, including the Rule 702 hearings on expert admissibility.
Step Four: Bellwether Trials
A small set of representative cases go to trial to test how juries respond to the evidence on both sides.
Step Five: Settlement or Continued Litigation
Depending on the bellwether outcomes, the parties may negotiate a broader settlement structure, or individual cases may proceed to trial separately.
Common Questions About the Ozempic Lawsuit
These are the questions people ask most often before deciding whether to move forward with an Ozempic lawsuit.
How long does an Ozempic lawsuit take to resolve? An Ozempic lawsuit of this scale often takes several years from filing to resolution. Given that bellwether trials are not expected to begin until late 2026 at the earliest, and a broad settlement is not anticipated before 2027, patience is genuinely part of the process.
Do I need to have stopped taking Ozempic to file a claim? Not necessarily, but you will need documented medical evidence of an injury that a doctor has connected to the drug, and ongoing treatment for that condition.
Can I still file if I only used Ozempic for a short time? It depends on the severity and documentation of your symptoms. Short term use combined with a confirmed diagnosis and significant medical intervention can still support a claim, while brief, undocumented symptoms are less likely to succeed.
Is an Ozempic lawsuit the same as a class action? No. An MDL consolidates Ozempic lawsuit cases for pretrial efficiency, but each plaintiff’s damages are evaluated individually, unlike a class action where everyone typically receives a similar payout.
Key Takeaways
- The Ozempic lawsuit refers to thousands of product liability claims against Novo Nordisk alleging the drug caused gastroparesis, intestinal obstruction, gallbladder disease, and NAION vision loss without adequate warning.
- Gastrointestinal claims are consolidated in MDL 3094 in the Eastern District of Pennsylvania, while vision loss claims sit in a separate federal MDL, alongside related state court consolidations in New Jersey.
- As of August 2026, the litigation remains in the pretrial phase, with no settlements finalized and bellwether trials expected to begin around late 2026 at the earliest.
- Qualifying for an Ozempic lawsuit generally requires a documented diagnosis supported by objective medical evidence, not just reported symptoms.
- Potential compensation can include medical expenses, lost wages, pain and suffering, and in some cases punitive damages.
- The FDA added ileus warnings to Ozempic’s label in January 2025, a development plaintiffs cite as evidence that risks were not adequately disclosed sooner.
- Anyone considering legal action should consult a qualified attorney to review their specific medical history and determine eligibility, since case evaluations are typically free.
Final Thoughts
The Ozempic lawsuit represents one of the most closely watched pharmaceutical litigations currently working through the federal court system. While no trials or settlements have concluded yet, the steady growth in filed cases and the upcoming expert hearings suggest meaningful developments are on the horizon for the Ozempic lawsuit. If you believe you were injured after taking Ozempic or a similar GLP-1 medication, gather your complete medical records, document your diagnosis with objective testing, and speak with an attorney who focuses on the Ozempic lawsuit litigation. Acting early can make a real difference in how your case is ultimately evaluated.